[MP-202416] Lurbinectedin (SCLC)
Last updated 22.07.2026
Project no.:
MP-202416
Report type:
Joint Clinical Assessment, JCA
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Maintenance treatment of adult patients with extensive-stage small cell lung cancer (ESSCLC)
Note:
This Joint Clinical Assessment (JCA) is being conducted in cooperation with Infarmed (National Authority of Medicines and Health Products) Portugal.
The joint clinical assessment will be published on the European Commission’s website: health.ec.europa.eu/publications/joint-clinical-assessment-report-tovorafenib-ojemda_en
Further background information can be found here: European health technology assessment
| Stage | Date |
|---|---|
| Start | 2nd quarter, 2025 |
| voraussichtlicher Abschluss | 3rd quarter, 2026 |